The company is a widely recognized biotechnology company. Based on our proprietary gene synthesis technology, as well as other technology and expertise related to life science research and applications, we have established a number of major platforms, including (i) life science service and product platforms to provide one-stop solutions for the global research community; (ii) a dynamic, biologics CDMO platform; and (iii) Bexer, a platform for industrial synthetic products. For the year ended December 31, 2024 (the “current year” and the “reporting period”), the above internally built platform achieved growth in terms of research and development to commercial delivery. The Group has also made significant investments in the field of cell therapy, which is expected to bring long-term value to the Group and shareholders. Since its establishment 22 years ago, the Group has been adhering to the mission of “using biotechnology to make people and nature healthier”. Customers' business needs are the Group's top priority and the fundamental foundation for our long-term development. We have been improving our competitiveness by providing quality, fast delivery, and cost-effective services and products. Internally, we focus on optimizing operational processes and procedures to continuously improve quality and delivery times. Externally, we actively enhance the value of strategic collaboration with business partners aimed at building a healthy biotechnology ecosystem. We hope to make more contributions to accelerating the development of the entire biotechnology and biopharmaceutical industry and jointly build the future of the industry. The Group's business operations cover more than 100 countries and regions around the world, with legal entities in mainland China (“China” or “Mainland China”), the United States, Hong Kong, Japan, Singapore, the Netherlands, the United Kingdom, South Korea, Spain, Australia and Macau, China. As of December 31, 2024, our professional team comprised approximately 5,568 members. The Life Sciences Services and Products segment provides services and products covering gene synthesis, oligonucleotide synthesis, peptide synthesis, protein production, antibody development, and life science equipment and consumables. By providing services for early research and discovery projects in pharmaceutical, biotechnology, and academic institutions, our business makes an important contribution to the global life science research community. Probio Technology Limited (“Probio Cayman” or “Boom”) is a subsidiary of the Group. As a leading CDMO, Flourish empowers global biologics innovation by providing seamless end-to-end solutions. Our comprehensive platform integrates discovery, development, and production services to streamline development processes, reduce time, and increase the success rate of biologics projects. By accelerating the development and production of life-changing biotherapeutics, we are committed to improving the lives of patients around the world and building a healthier future. Baisjie Biotechnology Co., Ltd. (“Baisjie”) is a subsidiary of the Group and is engaged in the industrial synthetic biology business. Baisjie uses our advanced protein engineering technology to develop products for the feed, food, grain processing and home care industries. We believe synthetic biology provides us with new technological and commercial opportunities.